Antisense Therapeutics (ASX: ANP)

Currency in

Last close As at 29/09/2023


0.00 (−2.94%)

Market capitalisation


Latest Insights

Share Price Performance

Price Performance
% 1M 3M 12M
Actual 30.8 (10.5) (28.4)
Relative 33.4 (11.6) (30.3)
52 week high/low A$0.1/A$0.0


Antisense Therapeutics is an Australian biotechnology company developing antisense oligonucleotide (ASO) therapies for the treatment of rare diseases. Its lead asset, ATL1102, is being investigated as a targeted anti-inflammatory therapy to treat Duchenne muscular dystrophy (DMD). In a positive strategic pivot, trial design was amended to a smaller Phase IIb study (n=42 vs 108) that should provide a nearer-term catalyst, if positive readouts are achieved. As a result of the reduced trial costs, the company’s cash runway is anticipated to be extended (net cash at end-June 2022 of A$19.2m) into Q4 CY23. Management envisages a need to raise funds in the mid-single digit (A$m) region, which it anticipates will fund operations to trial readouts in Q124.

Further insights



Healthcare Week 2023

Analyst of the week

Soo Romanoff

Soo Romanoff

Managing Director - Head of Content, Healthcare

Read latest




ASCO 2023 key takeaways



Machine learning in drug development

Subscribe to Edison

Get access to the very latest content matched to your personal investment style.

Sign up for free